Pharmacor Inc.

Company

Also known as: Pharmacor

Related News

AstraZeneca Advances Oral GLP-1 Drug and Defends Diabetes Patent in Australia

Jun 19, 2026

AstraZeneca is advancing its oral GLP-1 drug into Phase III trials while defending dapagliflozin patents in Australia. The company obtained an Australian court injunction against a generic competitor and has partnered with Evinova to use AI for clinical trials. India could be a future market for the oral GLP-1 drug pending global trial data.

AstraZeneca Secures Injunction Blocking Pharmacor's Generic Diabetes Drug Launch in Australia

Mar 10, 2026

AstraZeneca won a Federal Court injunction blocking Pharmacor from selling generic dapagliflozin products in Australia until a full patent trial. The patent expires October 22, 2027.

AstraZeneca Wins Injunction Blocking Generic Dapagliflozin Launch in Australia

Mar 02, 2026

The Federal Court of Australia granted AstraZeneca an interlocutory injunction on 16 February 2026 preventing Pharmacor from launching generic dapagliflozin products pending infringement proceedings, marking the second such injunction in three months.